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Abstract
Background: Ghana established its National Health Insurance Scheme (NHIS) in 2003 with the goal of ensuring
more equitable financing of health care to improve access to health services. This qualitative study examines the
challenges and consequences of medicines management policies and practices under the NHIS as perceived by
public and private service providers.
Methods: This study was conducted in health facilities in the Eastern, Greater Accra and Volta regions of Ghana
between July and August 2014. We interviewed 26 Key Informants (KIs) from a purposively selected sample of
public and private sector providers (government and mission hospitals, private hospitals and private standalone
pharmacies), pharmaceutical suppliers and NHIS district offices. Data was collected using semi-structured interview
guides which covered facility accreditation, reimbursement practices, medicines selection, purchasing and pricing of
medicines, and utilization of medicines. Codes for data analysis were developed based on the study questions and
also in response to themes that emerged from the transcripts and notes.
Results: Most KIs agreed that the introduction of the NHIS has increased access to and utilization of medicines by
removing cost barriers for patients; however, some pointed out the increased utilization could also be corollary to
moral hazard. Common concerns across all facilities were the delays in receiving NHIS reimbursements, and low
reimbursement rates for medicines which result in providers asking patients to pay supplementary fees. KIs
reported important differences between private and public sectors including weak separation of prescribing and
dispensing and limited use of drugs and therapeutic committees in the private sector, the disproportionate effects
of unfavorable reimbursement prices for medicines, and inadequate participation of the private sector providers
(especially pharmacies and licensed chemical sellers) in the NHIS.
Conclusions: Health providers generally perceive the NHIS to have had a largely positive impact on access to
medicines. However, concerns remain about equity in access to medicines and the differences in quality of
pharmaceutical care delivered by private and public providers. Routine monitoring of medicines use during the
implementation of health insurance schemes is important to identify and address the potential consequences of
medicines policies and practices under the scheme.
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Background
In 2003, Ghana set out to provide Universal Health
Coverage (UHC) to its citizens by establishing a National
Health Insurance Scheme (NHIS). The World Health
Organization (WHO) defines UHC as “access to key
promotive, preventive, curative and rehabilitative health
interventions for all at an affordable cost, thereby
achieving equity in access” [1]. Medicines constitute an
important component of health care interventions both
in terms of cost to the health care system and their effi-
cacy. The Forum on Universal Health Care Coverage
held in Mexico City, further highlighted access to afford-
able, quality, safe and effective medicines as an import-
ant element of UHC [2]. The inclusion of UHC in the
Sustainable Development Goals adopted by the United
Nations in September 2015 widens a window of oppor-
tunity to improve access to quality and affordable medi-
cines, especially in low and middle-income countries [3].
Ghana established the NHIS through a National
Health Insurance Law (Act 650) in 2003 to ensure more
equitable financing of health care and to improve access
to health services in the country [4]. This law abolished
the “cash and carry” system originally introduced in the
1980s. The National Health Insurance Act established a
National Health Insurance Authority (NHIA) to regulate
all health insurance schemes in the country and to im-
plement the NHIS [4]. The NHIS is primarily financed
by funds generated from a National Health Insurance
Levy (a 2.5 % levy on goods and services collected under
the Value Added Tax (VAT) system), 2.5 percentage
points of formal sector employees’ monthly social secur-
ity contributions, and premiums paid by subscribers in
the informal sector [5, 6]. Formal sector employees and
the self-employed who make social security contribu-
tions, children under the age of 18, individuals 70 years
old and above, pregnant women, indigents, categories of
differently-abled persons, persons with mental disorder,
and social security pensioners do not pay membership
premiums [7]. These groups constitute 69 % of active
NHIS members. As of December 2013, active member-
ship of the NHIS was 10.5 million representing 39 % of
the total population. The benefit package of the NHIS
covers 95 % of disease conditions in the country [5, 7].
A report published by the World Bank in 2013 indi-
cated that more than 50 % of patients seek care from the
private sector in Ghana [8]. Ghana has a private sector
development policy that, among other goals, aims to
build the capacity of private healthcare providers and in-
crease access to private sector health services for the
poor [9]. In line with this policy, the NHIA accredits
both private and public health facilities to provide ser-
vices covered by the NHIS. As of 2012 a total of 3,575
health service facilities had been accredited by the NHIS,
including 1,916 public facilities, 866 private hospitals,
and 207 mission facilities, as well as 324 pharmacies and
233 licensed chemical sellers (LCS) [10]. There are over
2,400 pharmacies and 10,000 LCS in the country [11].
Faith-based organizations (mission hospitals) constitute
an important network of health care providers in Ghana.
These providers tend to align more with the public sector
as they benefit from government subsidies and their staff
are normally on government payroll. The largest network
of this group is the Christian Health Association of Ghana
(CHAG).
Licensed chemical sellers and pharmacies tend to be
first point of call for patients because there are no con-
sultation fees, little or no waiting times and patients’
preference for self-medication [11]. LCS typically operate
in rural areas, while pharmacies predominantly serve
urban areas. LCS are limited by the Pharmacy Act of
Ghana to selling only class C (over the counter) medi-
cines (which account for about 30 % of total market
value) [12]. It is likely, that insurance policies and prac-
tices differentially affects access to quality and affordable
medicines at these facilities.
The NHIS has a periodically updated reimbursement
list of medicines which the scheme covers [13]. As of
2014, this list has 522 medicines, which are provided to
insured patients for free with no copayments [11, 13].
The NHIS determines fixed maximum reimbursement
prices for medicines on the list, based on the median
market price of each medicine [11]. Medicines are cur-
rently reimbursed on a fee-for-service basis, separately
from other services, which are reimbursed under the
Ghana Diagnosis-Related Group (GDRG) model. This
reimbursement model enables standalone drug outlets
to dispense medicines under coverage of the NHIS. Re-
imbursement prices for medicines covered by the NHIS
is the same for public and private providers [11, 13].
The NHIS in Ghana is the subject of numerous stud-
ies, which generally focused on variations in health-
seeking behavior based on insurance status. For example,
in a cross-sectional household survey of 365 malaria
patients, Fenny et al. showed that the patients with in-
surance are six times more likely to seek care from
regional or district hospitals, five times more likely to
seek care from health centers or clinics, and seven times
more likely to seek care from private hospitals or private
clinics as compared patients who are uninsured [14].
Few studies have focused on medicines and even fewer
examine how the NHIS affects access to medicines
through the private sector. Some reports have
highlighted increases in total national expenditure on
medicines, delays in medicines reimbursement, a de-
crease in the number of standalone pharmacies and LCS
participating in the NHIS over time, and supplier-
induced demand for medicines [11, 15, 16]. However it
is unclear whether and how these findings differ between
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private and public institutions. This qualitative study ex-
amines the issues generated by the medicines manage-
ment policies and practices introduced under Ghana’s
NHIS as perceived by providers. In particular, it eluci-
dates how these challenges and consequences differen-
tially affect public and private service providers. The
major pharmaceutical management practices the study
focuses on include reimbursement strategies for medi-
cines, medicines selection and use of formularies, pur-
chasing and pricing, and medicines utilization.
Methods
This study was conducted between July and August
2014 in the Greater Accra, Eastern and Volta regions of
Ghana. Health facilities and institutions were purposively
selected based on geographic accessibility, size (mix of
big and small health facilities) and familiarity with the
investigators. The facilities and institutions included
public sector providers (regional, district and mission
hospitals), private sector providers (private hospitals,
and private standalone pharmacies), pharmaceutical sup-
pliers and NHIS district offices. For the purpose of this
study, we classified mission hospitals as “public” for rea-
sons discussed in the background section.
Potential KIs were informed about the objectives of
the study and invited to take part in the interviews. KIs
were also asked to recommend other experts involved in
medicines management in other health facilities for the
study. In all, 26 KIs out of 29 agreed to participate and
only three of these were referrals. Table 1 shows the
number of KIs from each type of facility. Additional
information on the type of facilities participating KIs
worked is in Additional file 1.
Interviews were conducted using a semi-structured
interview guide to collect data on the experiences of KIs
and their institutions managing medicines under the
current health insurance policies and practices.
At the start of the interview, informed consent was soli-
cited verbally to those who agreed to participate. The inter-
view guide (Additional file 2) included questions about
insurance policies and practices regarding: (1) facility
accreditation, (2) reimbursement practices, (3) medicines
selection and use of formularies, (4) purchasing and pricing,
and (5) medicines utilization. These topics were adapted
from the four strategies described by Faden et al. for balan-
cing the competing goals of improving access to medicines,
encouraging appropriate use, and keeping costs affordable
[17]. Interviews lasted between 35 min to one hour. Four-
teen interviews were tape-recorded with the consent of the
KI. In the other cases where the interviewees refused to be
tape-recorded, detailed notes were taken.
Institutional Review Board Approval
The study protocol was reviewed and approved by Bos-
ton University’s Institutional Review Board.
Data analysis
Interview recordings were transcribed and coded together
with the interview notes. One of the investigators (PGA),
who is experienced in qualitative data analysis developed
codes based on the study questions and also in response
to themes that emerged from the transcripts and notes.
Responses from the public providers were compared with
those from private providers. For the purposes of this ana-
lysis, we treated mission hospitals as “public” since their
interaction with the NHIS system is similar to public facil-
ities. We also explored variations within each provider
type. Analysis focused on exploring both parallel and
divergent perceptions. We explored the potential relation-
ships among medicines management policies and prac-
tices and their consequences as reported by KIs. This is
presented in a loop diagram in Fig. 1.
Results
The results are presented according to the key areas of
medicines management: 1) Accreditation process and dis-
continuation of service provision under the NHIS; 2)
Reimbursement practices for public and private sector ser-
vice provision; 3) Selecting medicines for purchase and
use by facilities; 4) Purchasing and pricing of medicines;
and 5) Improving medicines utilization.
1. Accreditation process and discontinuation of
service provision under the NHIS
Most of the KIs reported that the accreditation process
was easy and efficient. Below is a list of reasons given by
Table 1 Number and type of facilities participating in each type
of study





5 Heads of pharmacy
Private hospital 4 3 Medical Directors
1 accountant
Private pharmacy 10 9 Superintendent
Pharmacists
1 Pharmacy Manager
District Insurance Office 2 1 District NHIS Manager
1 District NHIS Public
Relations Officer
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KIs from private hospitals and pharmacies for applying
for NHIS accreditation (It is obligatory for public facil-
ities to provide services under the NHIS).
– To serve their community members who have
health insurance
– To avoid losing their clients
– To make a profit
– To keep good working relationships with hospitals
(including filling prescriptions coming out of
hospitals)
– To become part of the main health care system
Anecdotal reports suggest that facilities (especially pri-
vate facilities) accredited by NHIS often drop out after
an initial period. All KIs in the public sector said it is
difficult for public providers to drop out of the NHIS or
suspend services to NHIS patients. In contrast, all KIs
from pharmacies and private hospitals shared the per-
ception that dropping out of the NHIS was quite com-
mon among their peers, although one mentioned it was
not common in his area. Providers gave multiple reasons
for dropping out of the NHIS. These reasons, some of
which were corroborated by KIs from the NHIS include
delays in reimbursement, unfavorable reimbursement
prices for medicines, not having enough business from
NHIS-affiliated patients, having enough patients who
can afford to pay for services out of pocket, the exten-
sive labor involved in processing claims, NHIS refusing
to reimburse for medicines dispensed on suspicion that
the claim was fraudulent, and poor relationships with
NHIS staff who sometimes demand informal payments.
KIs from two NHIS district offices confirmed the limited
participation of pharmacies and LCS in the NHIS. Only
one LCS (who had stopped serving NHIS clients at the
time of the study) have been accredited in these two dis-
tricts. The following quotes illustrate some of the rea-
sons providers drop out of the NHIS:
“Because it is not a big business, we do not want to set
up structures for it. We only receive 3–5 prescriptions
in a month.” – KI P002, Private Pharmacy
“They [NHIS] frustrate you for so many reasons […].
Once you do not give them kickback they delay the
vetting and submission of your claims. For the public
Fig. 1 Diagram summarizing medicines policies and management practices and their consequences under Ghana’s NHIS. Legend: Policies and
practices and independent attributes are presented in boxes. Consequences are presented in texts without boxes. Consequences and practices
predominant in the private sector are colored in purple. The arrows show the potential inter-relationships among policies and practices, and
their consequences
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sector they know they cannot collect any money from
them, so the focus is on the private sector.” – KI
PH001, Private Hospital
Instead of officially opting out of the scheme, some
reported other ways of avoiding NHIS clients:
“Sometimes we tell [NHIS] patients we do not have the
medicine. Though we have it, we prefer selling it to
individuals who can pay.” – KI P007, Private
Pharmacy
Two KIs from CHAG facilities said that most CHAG in-
stitutions have decided not to provide services under
NHIS, under the direction of their leadership. This deci-
sion (which coincided with our data collection period)
was due to facilities being owed seven or more months’ ar-
rears by NHIS, the high market prices of medicines com-
pared to the NHIS reimbursement prices, and the rapid
depreciation of the cedi, which results in facilities incur-
ring more cost if they do not get timely reimbursements.
Another KI from a CHAG facility gave an example of
how their facility is trying to strike the right balance
between suspending services and taking care of the
vulnerable:
“… For pregnant women we were giving them all the
routine drugs, paracetamol and malaria treatment.
But for antibiotics unfortunately they have to pay,
using the wards they have to pay [out of
pocket]….That is what we are practicing up to today.”
KI PU007, Mission Hospital
2. Impact of reimbursement practices on public and
private sector service provision
A majority of KIs from pharmacies (eight out of ten)
and all of the KIs from private hospitals felt it was not
fair that the reimbursement prices for medicines are the
same for both the public and private sector providers.
They felt that private providers incur additional ex-
penses, including payment of salaries, utilities, and taxes,
which are paid by the government for the public sector.
However, KIs from the NHIS said they have not received
any official complaint about the need to have higher re-
imbursement rates for private providers.
All KIs in both public and private sectors as well as
three (out of five) suppliers reported the NHIS medicine
reimbursement prices often fall below market prices and
the prices are not regularly updated. Some participants
blamed higher prices for medicines on a recently-
introduced government policy to charge VAT on medi-
cines. This tax has since been removed.
Constrained by low reimbursement rates, providers
face a dilemma: do they dispense medicines at the
current NHIS price and incur losses, or do they ask pa-
tients to pay the difference? One KI said the latter op-
tion has been discouraged by the NHIA. However
comments from other KIs, including an NHIS staff show
that this does happen:
“If the price is high, and the person wants the drug, he
may pay the difference. We call it ‘top-up’.” – KI
PH004, Private Hospital.
“Some co-payment [for medicines] exist, but they are
not permitted by the NHIS” – KI N001, NHIS
Another strategy used by providers to circumvent low
reimbursement rates for specific medicines is prescribing
a therapeutically equivalent alternative that has a higher
mark-up. For example, the reimbursement price of
amoxicillin capsules is below the supplier price. When
patients present with simple respiratory tract infections,
providers prefer prescribing amoxicillin/clavulanic acid
(a more expensive treatment) instead of amoxicillin only
(which is less expensive).
Consequences of delays in reimbursement
All of the providers, private and public, complained
about reimbursement delays (in some cases up to nine
months) which is also affects their ability to pay sup-
pliers on time. Suppliers confirmed that delays in reim-
bursement to facilities results in delays in getting paid
for their supplies. Accredited facilities, they noted, take
longer to pay compared to facilities that are not accre-
dited by the NHIS.
Suppliers mentioned various strategies they use to
force facilities to pay them in time. These include: char-
ging a premium price for medicines supplied to NHIS-
accredited facilities to offset delays (mentioned by one
supplier); lobbying facilities to get the NHIS to pay them
in time (two suppliers); approaching the facilities imme-
diately when they learn that the NHIS has paid them
(one supplier); and reducing supplies to the facility or re-
fusing to supply or participate in tenders altogether (four
suppliers).
3. Selecting medicines for purchase and use at health
facilities
KIs from both the private and public sector said that
they use the national Essential Medicine List (EML),
Standard Treatment Guidelines (STG), and the reim-
bursement list when deciding which medicines to stock
at their facilities. All KIs concurred that the reimburse-
ment list has become more important, though the STGs
are used as treatment protocols and for audit purposes.
All of the public facilities reported stocking, based on
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need, a few medicines outside the reimbursement list
and/or EML that they sell on a cash and carry basis.
An important difference exists between private and
public hospitals: the presence of drugs and therapeutics
committees (DTCs). All KIs from public hospitals re-
ported having DTCs in their facilities; in contrast, DTCs
are not generally available in private institutions. Only
one KI from a big private hospital reported having a
DTC. Facilities mentioned their DTCs guide the selec-
tion of medicines and approve the use of medicines out-
side the EML and reimbursement list; advise on rational
use of medicines; develop an institutional formulary; and
disseminate information on clinical claims management.
4. Purchasing and pricing of medicines
Purchasing of medicines
Public and private sector providers utilize different pro-
curement strategies. Government hospitals are required
to use the Central Medical Stores (CMS)/Regional Med-
ical Stores (RMS) as their first supply source. Faith-
based organizations (mostly Catholic hospitals and
clinics) have another source in addition to the CMS and
RMS; they source products from the National Catholic
Secretariat (NCS), which does pooled procurement for
affiliated facilities. The CMS, RMS, and NCS procure
large volumes of medicines by tender.
KIs in the private sector, on the other hand, reported
they are not able to purchase by competitive tender (due
to the small volumes they procure). Instead, they com-
pare price lists from suppliers for the best price, some-
times negotiating with suppliers using the
reimbursement list. Table 2 summarizes the advantages
the KIs reported for competitive tender and negotiation
or direct procurement. Suppliers acknowledged that they
may reduce prices during competitive tenders
“[Public facilities providing] NHIS purchase by
competitive tender. We tend to come down a little on
their prices. In fact, it should have been the opposite
since they will not pay you on time, but because of
tender we give them lower prices.” KI S004, Supplier.
While one private sector KI mentioned private pro-
viders are not entirely barred from accessing medicines
through the CMS and RMS, others highlighted major
difficulties in getting medicines from the public medical
stores. Sales by the CMS/RMS to private providers are
cash and carry only, and the CMS/RMS prioritizes pub-
lic facilities over private facilities.
Pricing of medicines
Mark-ups applied to medicines varied widely between
and within public and private sector providers, as well as
across medicines. All KIs from suppliers said they are
guided by the NHIS reimbursement list when determin-
ing their selling prices. Suppliers reported mark-ups ran-
ging on average between 10 and 40 %.
At the retail level, private hospitals generally reported
adding a mark-up of 25 to 40 % for medicines that are
not on the reimbursement list (The exception was one
KI who said he adds 1 or 2 %, but this was stated un-
surely). Private pharmacies reported using mark ups be-
tween 30 and 50 % for the same category of medicines
depending on the location of the facility (facilities in af-
fluent neighborhoods had higher mark-ups), the price of
the medicine (expensive medicines had lower mark-ups),
demand for the product (products with low demand had
higher mark-ups), and making financial transactions eas-
ier (rounding up mark ups to the nearest round
amount). Public facilities reported mark-ups ranging
from 15 to 40 % for medicines not on the reimburse-
ment list, which their patients pay for out of pocket.
5. Improving medicines utilization
Almost all KIs (including the two KIs from the NHIS)
felt that the NHIS has led to increased utilization of
medicines, reporting: patients who could not afford to
purchase medicines now have free access to them; and,
the NHIS has enabled patients to stop purchasing in-
complete doses of medicines, especially antibiotics.
KIs from both the private pharmacies and the public hos-
pitals also mentioned negative impacts: over-prescribing by
those providers who also dispense medicines or have phar-
macies in their facilities; and “provider shopping” by pa-
tients. Because there is no centralized tracking system,
patients go from facility to facility with the same complaint,
soliciting medicines, which according to KIs, they try to re-
sell on the black market. Thus some negative impacts are
provider-driven, while others are patient-driven.
“Some clients assume they must by all means benefit,
so you find a few of the clients going from one facility
to the other to access the medications – without
finishing their previous medications” KI PU001, Public
Hospital
Table 2 Advantages of competitive tender versus direct
procurement reported by KIs
Competitive tender Competitive negotiation/Direct
procurement
-Lower procurement prices
(reported by 17 KIs)
-Less expensive process (reported by
1KI)
-Assurance of getting quality
medicines (6 KIs)
-Wider pool of suppliers to select from
(1KI)
-Most suppliers deliver medicines to
providers for free (1 KI)
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NHIS does not reimburse medicines dispensed from a
facility below the level of care that medicine is assigned
in the EML. While the purpose of this is to promote ap-
propriate use of medicines, three KIs working in the pri-
vate sector observed that this has a negative impact on
access to some of these particular medicines. Patients
may have to travel long distances or wait to get to a
referral facility to access these medicines, including med-
icines that could be given to stabilize patients before
referral.
All KIs from private pharmacies and public hospitals
reported that it is common in private hospitals for pre-
scribers to dispense or have influence over the activities
of those dispensing. This goes against the recognized
best practice of clearly separating the roles of prescribing
and dispensing (This was not seen to occur in the public
sector). KIs from private pharmacies expressed concerns
about how this affects pharmaceutical care and how pre-
scriptions from private hospitals do not get to private
pharmacies.
“Physicians prescribe what they can dispense, not what
the patient needs….Pharmacy practice is now just a
practice without patients.” – KI P006, Private
Pharmacy
Two KIs from private hospitals however asserted that
there is separation of prescribing and dispensing in pri-
vate hospitals. One mentioned this cautiously, noting
that the NHIS requires the hospital pharmacy to be
manned by a dispensing technician or pharmacist, but
this is difficult because of lack of human resources.
KIs were asked whether government programs that seek
to promote the appropriate use of medicines also reach
the private sector. Eleven KIs (five from private pharma-
cies, and three each from private and public hospitals)
agreed that the private sector is sometimes involved in
these initiatives. Two KIs from private pharmacies further
observed, however, that it is not mandatory for private
sector providers to participate, unlike the public sector.
Private hospitals mentioned receiving technical assistance
without specifying if this assistance relates to medicines.
6. Interrelationships among management policies and
practices and their consequences
Figure 1 presents a summary of the policies and prac-
tices examined in this study, their consequences re-
ported by KIs, and the potential relationships among
these. The figure also highlights how the consequences
of these policies and practices differentially affect public
and private sectors. The text presented in boxes describe
policies and practices and independent attributes. The
text presented without boxes show the consequences of
these policies and practices. Consequences, policies and
practices predominant among private sector providers
are colored in purple in the figure.
Discussion
The experiences revealed in this study show that, despite
the overall strides Ghana has made towards universal
health care coverage and improved access to medicines,
critical challenges relating to access and use of medi-
cines under the NHIS persist. In the sections below, we
first discuss general cross-cutting themes that emanated
from the study. Following this, we highlight important
differences in the consequences of medicines manage-
ment policies between private and public providers.
Cross cutting themes
Most of those interviewed agreed that the introduction
of the NHIS has increased access and utilization of med-
icines, due to removal of cost barriers for patients. This
concurs with findings from other studies, including
those that have documented Ghana’s progress towards
achieving Millennium Development Goal 8E, which
aimed to provide access to affordable essential medicines
in developing countries [18–20]. The importance of the
financial protection provided by UHC in enhancing
access to medicines is documented. A 2007 to 2010
household survey on access to medicines for chronic
diseases in five low- and middle-income countries, in-
cluding Ghana, showed that those who are insured are
up to three times more likely to have access medicines
for chronic diseases, compared to those who are unin-
sured [21]. Increasing access and utilization bears the
risk of inappropriate use if medicines are not managed
adequately. For example, a study by Witter et al. on the
NHIS found that medicines utilization, measured by
number of medicines per prescription, increased from
4.5 in 2004 to 6.0 in 2008 [22]. The WHO and the Inter-
national Network for Rational Use of Medicines recom-
mends an optimum average number of medicines
prescribed per consultation of ≤3 [23, 24]. This recom-
mended figure is less than half that of Ghana’s in 2008.
Increased utilization could also be due to moral hazard,
where patients frequently use services that they do not
need because they do not have to pay for it. While the
absence of copayments for medicines under the NHIS
will remove financial barriers to access to medicines, this
very access also creates opportunities for overutilization
of medicines [17]. Increased utilization of medicines
may also be due to supplier- or prescriber-induced
demand; this can be exacerbated by limited separation of
prescribing and dispensing, especially in the private
sector [15]. Increase utilization in the absence of any
clinical need could harm patients and –in the case of
Ashigbie et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:6 Page 7 of 10
anti-infective medication- result in the development of
antimicrobial resistance.
The NHIS reimbursement list appears to be accom-
plishing its purpose - streamlining purchases and con-
taining costs - as suppliers reported using it as a
guide when pricing their products and providers re-
ported taking it into account when bargaining for or
purchasing medicines. Thus the reimbursement list
has the potential to control the price of medicines.
There is limited documented evidence on the effects
of formularies in reducing medicines prices in low
and middle income countries [17]. The use of formu-
laries has been shown in some places to decrease the
use of imported and expensive medicines, for ex-
ample, reducing the rate of growth for total medical
and medicines expenditures in China and Taiwan [25,
26]. A balance must be struck between cost contain-
ment on the one hand, and the sustainability of
health facilities and industry on the other, to ensure
reliable availability of medicines. The practice of ask-
ing patients to pay supplementary fees to make up
for low reimbursement prices (despite being discour-
aged by the NHIS) presents an opportunity for pro-
viders to charge arbitrary prices. While this allows
the profit making inherent in the private sector, it
may interfere with equity in access. Additionally, it
threatens the goal of the NHIS to provide financial
protection to patients.
Another common concern reported across all facil-
ities was the delay, up to 7 to 9 months, in receiving
reimbursements from NHIS. This has also been re-
ported by other studies [11, 27, 28]. As shown in
Fig. 1, these delays affect both the providers and the
suppliers. In response, suppliers adopt strategies such
as refusing to re-supply providers, patients ultimately
suffer from being denied treatment due to financial
barriers or stock-outs.
Loop diagrams have been used to show complex rela-
tionships among health systems policies and practices
[29, 30]. As shown in the loop diagram in Fig. 1, the web
of interrelationships among medicines policies and man-
agement practices and their consequences can be com-
plex. A policy or practice could have unintended and
negative consequences in addition to its desired effects.
For example, not having copays for medicines will im-
prove access to and promote rational use of medicines.
However, this policy can also promote overutilization of
medicines and a concomitant increase in the value of
claims. The sustainability of the scheme can be jeopar-
dized as claims reimbursement delay and facilities drop
out of the scheme. It is thus important in the design of
insurance schemes, to have a system of monitoring and
addressing unintended consequences of medicines pol-
icies and management practices.
Major differences between private and public providers
Participation of providers
Though KIs from both private and public sectors were
satisfied with the process by which NHIA accredits
health facilities, there is limited participation of LCSs
and private pharmacies. At the time of the study, no
LCSs or private pharmacies were providing services
under NHIS coverage in two districts we visited. Private
providers are more adversely affected by the factors that
discourage NHIS participation (Fig. 1). Delays in reim-
bursement, unfavorable reimbursement prices for medi-
cines, and the labor involved in processing claims likely
have more impact on private sector providers, especially
LCS, private pharmacies and small hospitals, which
operate with little capital and low human resource cap-
acity. These explain why it is more common for private
facilities to drop out of the NHIS and deny NHIS pa-
tients treatment. This does not auger well for Ghana’s
private sector engagement policy. Considering the large
proportion of private providers in the country, their re-
tention in the NHIS program is important in improving
access to medicines.
Separation of prescribing and dispensing
Separation of dispending and prescribing functions may
be relatively poor in the private sector. As shown in
Fig. 1, the limited separation of prescription and dis-
pensing, coupled with fee-for-service reimbursement for
medicines, may create an environment for supplier-
induced demand. This in turn leads to increased use of
higher cost, inappropriate medicines and limited pre-
scriptions reaching private pharmacies and LCS. In
Zimbabwe, prescriptions by dispensing doctors include
about twice the number of medicines when compared to
prescriptions from non-dispensing doctors [31]. An even
more extreme example come from Malaysia, where dis-
pensing doctors were documented to prescribe seven
times more medicines than non-dispensing doctors [32,
33]. Separating the roles of prescribing and dispensing
limits over-prescription by dispensing doctors and in-
centives for inappropriate selection of medicines [33].
Protecting professional boundaries has been reported
as a barrier to separating prescribing from dispensing
[34]. KIs in this study also mentioned limited human re-
sources as a barrier – there may not be enough
personnel available to divide the roles. Despite these
challenges, separation is necessary in the delivery of
quality pharmaceutical services.
Use of drug and therapeutic committees
The absence of DTCs in private hospitals should be of
concern to policy makers. DTCs have been shown to
contribute to optimizing patient health outcomes, con-
trolling expenditure, managing formularies effectively,
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and educating health workers on medicines [35–41].
The frequent absence of DTCs in private hospitals pre-
sents a situation of inadequate oversight of medicines
use in this sector. As patients now have equal opportun-
ities, depending on their location and preference to seek
services from the public sector and accredited private
providers, implementing DTCs in the private hospitals is
necessary to promote rational use in all sectors.
Purchasing
Public facilities reported purchasing by tender or sour-
cing their medicines from the medical stores, which pur-
chase in high volumes and therefore at lower prices.
Private facilities more often engaged in negotiated or
direct procurement, often in smaller volumes. Generally,
bulk purchasing and competitive tenders could lead to
lowered prices. For example, bulk purchasing of selected
essential medicines saved the government of Delhi,
India, 30 % of its annual medicines expenditure [42]. In
another case, six small islands in the South Pacific
jointly employed this strategy to achieve the economies
of scale [43]. Private providers in Ghana are likely con-
fronting higher procurement prices due to their frac-
tured purchasing. Supporting private providers to
purchase products from medical stores would ensure
they have access to better prices and higher quality med-
icines (as the medical stores are likely to have more
technical expertise and resources to ascertain medicines
quality). This could also benefit the medical stores by in-
creasing their customer base and negotiating and pur-
chasing power. However, they might need to adapt some
of their practices to meet the particular requirements of
the private sector.
There are some limitations to this study. Due to the
centralized governance system in Ghana, we expect our
findings from the three regions to be representative of
the country. However, extrapolating the findings of this
study to other countries need to be done with caution as
the health systems structure and organization, culture,
and policies may be different. Additionally, we could not
get a KI from LCS to participate in the study. Even
though LCS perform the same role as private pharma-
cies, we acknowledge our findings might have missed
some of their perceptions.
Conclusion
The findings from this study suggest that there are posi-
tive and negative consequences of medicines manage-
ment policies and practices under Ghana’s NHIS. In
addition to confirming findings from previous studies of
Ghana’s NHIS, this study provides new insight on how
medicines management policies and practices differen-
tially affect public and private providers. Delays in reim-
bursement and low reimbursement prices have been
identified as particular challenges that affect private sec-
tor providers more and have led to their limited partici-
pation in the scheme. Additionally, there may be
inadequate oversight of medicines use in the private sec-
tor due to the lack of separation between prescribing
and dispensing and the limited use of DTCs. Based on
these findings, the following are some options to con-
sider to improve the quality of pharmaceutical care
under the NHIS.
1. Implement a routine system for monitoring and
evaluating the effects of insurance policies on
medicines use in the public and private sectors.
2. Frequently update reimbursement prices to reflect
market prices. It may also be worthwhile to have
reimbursement rates that are reasonably different
between public and private providers.
3. While the limited human resource in the country
will not make separation of the role of prescribing
and dispensing possible in all private hospitals, the
concept should be promoted in big private hospitals.
This should be made one of the criteria for
upgrading facilities to higher levels of care.
4. The use of DTCs should be promoted in private
hospitals. The existence of a DTC should also be
one of the indicators for upgrading health facilities
to higher levels of care.
5. Private hospitals should be allowed to purchase from
CMS and RMS if they chose to, so they have access
to quality products and potentially better prices.
Equitable access to quality and affordable medicines
should continue to be a key consideration when designing
both insurance policies and national accreditation pro-
cesses. Recognition of their possible consequences on the
various categories of providers including the private and
public sector requires additional attention and assessment.
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